These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 9420033)
21. Drug therapy during continuous arteriovenous hemofiltration. Keller E Adv Exp Med Biol; 1989; 260():117-27. PubMed ID: 2696363 [No Abstract] [Full Text] [Related]
22. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. Bergan T; Michalsen H; Malmborg AS; Pedersen SS; Pressler T; Storrøsten OT; Strandvik B Chemotherapy; 1993; 39(6):369-73. PubMed ID: 8222862 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359 [TBL] [Abstract][Full Text] [Related]
24. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Konishi K; Suzuki H; Saruta T; Hayashi M; Deguchi N; Tazaki H; Hisaka A Antimicrob Agents Chemother; 1991 Aug; 35(8):1616-20. PubMed ID: 1929334 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Somani P; Freimer EH; Gross ML; Higgins JT Antimicrob Agents Chemother; 1988 Apr; 32(4):530-4. PubMed ID: 3377464 [TBL] [Abstract][Full Text] [Related]
27. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. Bellmann R; Egger P; Gritsch W; Bellmann-Weiler R; Joannidis M; Dunzendorfer S; Wiedermann CJ Int J Clin Pharmacol Ther; 2002 Apr; 40(4):142-9. PubMed ID: 11996208 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280 [TBL] [Abstract][Full Text] [Related]
30. Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections. Sexton DJ; Wlodaver CG; Tobey LE; Yangco BG; Graziani AL; MacGregor RR Chemotherapy; 1991; 37 Suppl 2():26-30. PubMed ID: 1879184 [TBL] [Abstract][Full Text] [Related]
31. Treatment of tularemia with imipenem/cilastatin sodium. Lee HC; Horowitz E; Linder W South Med J; 1991 Oct; 84(10):1277-8. PubMed ID: 1925735 [TBL] [Abstract][Full Text] [Related]
32. Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System. Por ED; Akers KS; Chung KK; Livezey JR; Selig DJ J Clin Pharmacol; 2021 Sep; 61(9):1182-1194. PubMed ID: 33811332 [TBL] [Abstract][Full Text] [Related]
33. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Pea F; Viale P; Lugano M; Pavan F; Scudeller L; Della Rocca G; Furlanut M Am J Kidney Dis; 2004 Dec; 44(6):1097-102. PubMed ID: 15558532 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses. Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815 [TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Reed MD; Kliegman RM; Yamashita TS; Myers CM; Blumer JL Antimicrob Agents Chemother; 1990 Jun; 34(6):1172-7. PubMed ID: 2393278 [TBL] [Abstract][Full Text] [Related]
37. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Balfour JA; Bryson HM; Brogden RN Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235 [TBL] [Abstract][Full Text] [Related]
38. The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. Rolando N; Wade JJ; Philpott-Howard JN; Casewell MW; Williams R J Antimicrob Chemother; 1994 Jan; 33(1):163-7. PubMed ID: 8157557 [No Abstract] [Full Text] [Related]
39. Clinical pharmacokinetics during continuous haemofiltration. Bressolle F; Kinowski JM; de la Coussaye JE; Wynn N; Eledjam JJ; Galtier M Clin Pharmacokinet; 1994 Jun; 26(6):457-71. PubMed ID: 8070219 [TBL] [Abstract][Full Text] [Related]
40. Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. Mayer M; Tophof C; Opferkuch W Infection; 1988; 16(4):225-8. PubMed ID: 3182087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]